Drug Profile

IBI 3016

Alternative Names: IBI-3016

Latest Information Update: 27 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Innovent Biologics
Class Antihypertensives; Small interfering RNA
Mechanism of Action Angiotensinogen expression inhibitors; RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Hypertension

Most Recent Events

20 Jan 2026 Innovent Biologics plans a phase II trial for Hypertension in China (SC, Injection) in February 2026 (NCT07352969)
09 Nov 2025 Preliminary efficacy and adverse events data from a phase I trials in Hypertension released by Innovent Biologics
31 Jul 2024 Phase-I clinical trials in Hypertension in China (SC) (NCT06501586)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com